No. 23-1219-RGA against Defendants Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc. (“Taro”) in connection with Taro’s submission of an Abbreviated New Drug Application (“ANDA”) to the U.S. Food and Drug Administration seeking, inter alia, approval for a generic version of Plaintiffs’ 2.5 mg Xarelto® product prior to the expiration of U.S. Patent No. 10,828,310 (“the ’310 patent”); and WHEREAS, Plaintiffs are engaged in related litigations against Taro and a number of defendants in connection with the ’310 patent, which are coordinated and consolidated under MDL No. 21-3017-RGA and C.A.

No. 21-314-RGA-LDH (consolidated), which are currently stayed pending final resolution of the appeal of Mylan Pharmaceuticals Inc. et al. v. Bayer Pharma AG, IPR2022-00517 (PTAB), see Bayer Pharma Aktiengesellschaft v. Mylan Pharms.

Inc., No. 2023- 2434 (Fed. Cir.); and WHEREAS, the parties wish to streamline discovery and conserve their and the Court’s resources; NOW, THEREFORE, Plaintiffs and Taro hereby STIPULATE, and request that the Court ORDER, as follows:

No. 23-1219-RGA all discovery requests served by Taro or jointly by the defendants in C.A.

Plaintiffs will deem served upon Taro all of Plaintiffs’ discovery responses and all parties’ court filings in C.A.